article

Skip to content The CRC Digest FIERCE Study: Trifluridine/Tipiracil With Radiation in Rectal Cancer — Clinical Colorectal Cancer Results from the FIERCE study have been published in Clinical Colorectal Cancer. This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The

Skip to content The CRC Digest Phase II: Pembrolizumab Plus Capecitabine and Bevacizumab in MSS Metastatic CRC — Clinical Colorectal Cancer Clinical Colorectal Cancer. This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC Digest — crcdigest.com

Skip to content The CRC Digest AZUR-4: Neoadjuvant Dostarlimab Plus Chemotherapy in MSS Colon Cancer — Clinical Colorectal Cancer The AZUR-4 trial protocol has been published in Clinical Colorectal Cancer. This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC

Skip to content The CRC Digest Long-Term Results: Adjuvant Chemotherapy After Liver Metastasis Surgery (JCOG0603) — Journal of Clinical Oncology Journal of Clinical Oncology. This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC Digest — crcdigest.com

Skip to content The CRC Digest ♥ LIVING WITH CRC Circulating Tumor DNA Testing May Increase Fear of Recurrence in Some Colorectal Cancer Survivors — Psycho-Oncology Researchers interviewed colorectal cancer survivors enrolled in the DYNAMIC trials, which used ctDNA testing to guide decisions about adjuvant chemotherapy after surgery. While many patients valued

Skip to content The CRC Digest ▸ TREATMENT HER2 Amplification May Predict Resistance to Anti-EGFR Therapy in Metastatic Colorectal Cancer — ESMO Gastrointestinal Oncology An exploratory analysis from the CAPRI-2 GOIM trial examined HER2 gene alterations in patients with RAS/BRAF wild-type, microsatellite stable metastatic colorectal cancer treated with FOLFIRI chemotherapy plus

Skip to content The CRC Digest ◆ TRIAL DATA STRATEGIC-1 Trial Defines Optimal Treatment Sequence for RAS/BRAF Wild-Type Metastatic Colorectal Cancer — Signal Transduction and Targeted Therapy The Phase III STRATEGIC-1 trial (NCT01910610) compared different sequences of chemotherapy combined with either anti-EGFR antibodies (cetuximab/panitumumab) or anti-angiogenic drugs (bevacizumab) in patients

Skip to content The CRC Digest ▪ SCREENING Circulating Tumor DNA Before Surgery Predicts Recurrence After Liver Metastasis Resection — Clinical Cancer Research Researchers analyzed blood samples from 116 patients with metastatic colorectal cancer confined to the liver who underwent surgery after chemotherapy. They measured circulating tumor DNA (ctDNA)—fragments of cancer

Skip to content The CRC Digest ◆ TRIAL DATA Perioperative Pembrolizumab Shows High Complete Response Rate in MSI-H/dMMR Localized Colorectal Cancer — Journal of Clinical Oncology Journal of Clinical Oncology. MSI-H/dMMR tumors have defects in DNA repair machinery that make them highly responsive to immunotherapy. What this means If you

Skip to content The CRC Digest ♥ Study explores how ctDNA testing affects fear of recurrence in colorectal cancer survivors Researchers examined the psychosocial impact of circulating tumor DNA testing in early-stage colorectal cancer survivors from three randomized trials, focusing on how this emerging prognostic biomarker influences fear of cancer recurrence.